BF2.649 in Patients With OSA, Still Complaining of EDS and Refusing to be Treated by CPAP.
Phase 3
Completed
- Conditions
- Obstructive Sleep ApneaExcessive Daytime Sleepiness
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-02-22
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- Bioprojet
- Target Recruit Count
- 268
- Registration Number
- NCT01072968
- Locations
- 🇫🇷
Centre Hospitalier Universitaire de Grenoble, Grenoble, France
BF2.649 in Patients With OSA and Treated by CPAP But Still Complaining of EDS
Phase 3
Completed
- Conditions
- Excessive Daytime SleepinessObstructive Sleep Apnea
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-02-19
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- Bioprojet
- Target Recruit Count
- 244
- Registration Number
- NCT01071876
- Locations
- 🇫🇷
CHU Grenoble, Grenoble, France
Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy
Phase 3
Completed
- Conditions
- NarcolepsyCataplexyExcessive Daytime Sleepiness
- Interventions
- Drug: BF2.649 add on Modafinil
- First Posted Date
- 2010-02-11
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- Bioprojet
- Target Recruit Count
- 14
- Registration Number
- NCT01067235
- Locations
- 🇨ðŸ‡
Neurocenter (EOC) of Southern Switzerland, Lugano, Switzerland
Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy
Phase 3
Completed
- Conditions
- Sleep DisordersCataplexyNarcolepsyExcessive Daytime Sleepiness
- Interventions
- First Posted Date
- 2010-02-11
- Last Posted Date
- 2012-06-11
- Lead Sponsor
- Bioprojet
- Target Recruit Count
- 110
- Registration Number
- NCT01067222
- Locations
- 🇨ðŸ‡
Neurocenter (EOC) of Southern Switzerland, Lugano, Switzerland
Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease
Phase 3
Completed
- Conditions
- Parkinson's Disease
- Interventions
- Drug: BF2.649 (Pitolisant)
- First Posted Date
- 2010-02-10
- Last Posted Date
- 2013-04-12
- Lead Sponsor
- Bioprojet
- Target Recruit Count
- 273
- Registration Number
- NCT01066442
- Locations
- 🇩🇪
Klinik für Neurologie Universitätsklinikum, Marburg, Germany
Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease
Phase 3
Completed
- Conditions
- Parkinson's Disease
- Interventions
- Drug: BF2.649 (pitolisant)
- First Posted Date
- 2009-12-21
- Last Posted Date
- 2013-04-12
- Lead Sponsor
- Bioprojet
- Target Recruit Count
- 268
- Registration Number
- NCT01036139
- Locations
- 🇫🇷
Pr Arnulf, Paris, France
Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients
Phase 2
Completed
- Conditions
- Excessive Daytime SleepinessParkinson's Disease
- Interventions
- Drug: PlaceboDrug: BF 2.649 20 mgDrug: BF 2.649 40 mgDrug: BF 2.649 5 mgDrug: BF 2.649 10 mg
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2012-06-11
- Lead Sponsor
- Bioprojet
- Target Recruit Count
- 108
- Registration Number
- NCT00642928
- Locations
- 🇫🇷
Pitié-Salpêtrière Hospital, Paris, France
© Copyright 2025. All Rights Reserved by MedPath